Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
Retrieved on:
Tuesday, April 18, 2023
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Talazoparib, Neutropenia, Atri, DNA, Circulating tumor DNA, AACR, Febrile neutropenia, PM, Natural history, Partnership, DDR, Progression-free survival, ADP, Neoplasm, Effectiveness, Roche, Clinical trial, Therapy, Pharmacokinetics, Ataxia, Pardi, Toxicity, Doctor of Philosophy, CBR, ORR, Biomarker, MRR, MD, Patient, Anemia, AM, BRCA, Infrared spectroscopy correlation table, Ovarian cancer, PARP, Thrombocytopenia, ATR, Safety, Aplastic anemia, Disease, Pharmaceutical industry, Medical imaging, Powder metallurgy, Reparenting
We are particularly encouraged by the depth of response and duration of treatment,” said Maria Koehler, MD, PhD, Chief Medical Officer of Repare.
Key Points:
- We are particularly encouraged by the depth of response and duration of treatment,” said Maria Koehler, MD, PhD, Chief Medical Officer of Repare.
- Key highlights from the data presented at the 2023 AACR Annual Meeting include:
Camonsertib combination resulted in durable clinical benefit across tumor types and different genomic alterations, regardless of choice of PARPi and presence of platinum resistance. - Early ctDNA molecular responses in 66% (31/47) of evaluable patients confirms antitumor activity of low dose, intermittent PARPi + ATRi therapy.
- The molecular response rate (MRR) was significantly higher in patients with clinical benefit (83%) compared to those without (48%; p=0.015), confirming treatment effect.